8-K: Verastem's AVMAPKI FAKZYNJA CO-PACK Receives FDA Approval for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology's AVMAPKI FAKZYNJA CO-PACK has been granted accelerated FDA approval as the first treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.

Summary

• Verastem Oncology announced that the FDA has approved AVMAPKI FAKZYNJA CO-PACK for treating adult patients with recurrent Kirsten rat sarcoma viral oncogene homolog mutated (KRAS mt) low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
• The approval is based on the Phase 2 RAMP 201 study, which showed a 44% overall response rate in patients with KRAS mutant recurrent LGSOC.
• This indication has been granted under accelerated approval based on the tumor response rate and duration of response, with continued approval contingent upon verification and description of clinical benefit in a confirmatory trial.
• AVMAPKI FAKZYNJA CO-PACK is expected to be available in the U.S. within one week.
• Verastem is committed to providing patient access and reimbursement support through its Verastem Cares program.

Sentiment

Score: 9

Explanation: The document is highly positive due to the FDA approval of a new treatment for a rare cancer, which addresses a significant unmet need. The accelerated approval and positive clinical trial results contribute to the strong positive sentiment.

Positives

• AVMAPKI FAKZYNJA CO-PACK is the first FDA-approved treatment specifically for KRAS-mutated recurrent LGSOC.
• The accelerated approval was granted well ahead of the June 30, 2025 PDUFA action date.
• The Phase 2 RAMP 201 trial showed a significant overall response rate of 44% in patients with KRAS mutant recurrent LGSOC.
• Verastem Cares program offers patient access and reimbursement support services.
• The company believes AVMAPKI FAKZYNJA CO-PACK is also the first-ever oral, novel/novel combination therapy approved in oncology.

Negatives

• Continued approval for the indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
• Possible serious side effects with AVMAPKI FAKZYNJA CO-PACK include ocular disorders, skin toxicities (rash), hepatotoxicity, rhabdomyolysis, and fetal harm when administered during pregnancy.
• The most common side effects include increased levels of an enzyme in the blood (CPK), nausea, fatigue, abnormal liver test (AST), and rash.

Risks

• The continued approval is contingent on the verification and description of clinical benefit in a confirmatory trial.
• There are potential serious side effects associated with AVMAPKI FAKZYNJA CO-PACK, including ocular disorders, skin toxicities, hepatotoxicity, rhabdomyolysis, and fetal harm.
• The company faces risks related to the launch and adoption of the product, including establishing favorable pricing and securing reimbursement coverage.
• There are competitive developments affecting the product candidates.
• The company may not have sufficient cash to fund its contemplated operations, including certain of its product commercialization and development programs.

Future Outlook

Verastem is progressing the confirmatory Phase 3 trial, RAMP 301, to continue supporting the ongoing body of research of this combination in women with and without a KRAS mutation, and is conducting clinical trials with avutometinib with and without defactinib in RAS/MAPK-driven tumors as part of its Raf And Mek Program or RAMP.

Management Comments

• Dan Paterson, president and chief executive officer of Verastem Oncology, stated that the approval represents not only the first-ever FDA-approved treatment specifically for this rare cancer but also a new day for people living with this disease who have been in desperate need of new treatment options.
• Rachel Grisham, M.D., Section Head, Ovarian Cancer at Memorial Sloan Kettering Cancer Center, said that the approval of avutometinib plus defactinib brings a much-needed therapeutic option to patients and establishes this combination as the new standard of care for women with recurrent low-grade serous ovarian cancer harboring a KRAS mutation.
• Professor Susana Banerjee, M.B.B.S., M.A., Ph.D., F.R.C.P, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, stated that the approval changes the treatment possibilities for RAS/MAPK-pathway-driven cancers and that they now need to build on this milestone to bring this new treatment to patients around the world.

Industry Context

This approval marks a significant advancement in the treatment of KRAS-mutated recurrent LGSOC, a rare and difficult-to-treat cancer, as it is the first FDA-approved therapy specifically for this disease, addressing a critical unmet need in the oncology space.

Comparison to Industry Standards

• Prior to this approval, there were no FDA-approved treatments specifically for KRAS-mutated recurrent LGSOC, setting AVMAPKI FAKZYNJA CO-PACK apart from existing therapies.
• The 44% overall response rate observed in the RAMP 201 trial is a notable improvement compared to historical treatment outcomes for this patient population.
• The combination therapy approach of AVMAPKI and FAKZYNJA is a novel strategy designed to provide a more complete blockade of the signaling that drives the growth and drug resistance of RAS/MAPK pathway-dependent tumors.

Stakeholder Impact

• Patients with KRAS-mutated recurrent LGSOC now have a new treatment option.
• Healthcare professionals have a new tool to treat this rare cancer.
• Verastem Oncology benefits from the FDA approval and potential revenue from AVMAPKI FAKZYNJA CO-PACK.
• The low-grade serous ovarian cancer community is hopeful and excited about the potential benefits of this treatment and the progress toward improving the diagnosis, awareness, and research for LGSOC.

Next Steps

• AVMAPKI FAKZYNJA CO-PACK is expected to be available for adult patients with KRAS-mutated recurrent LGSOC in the U.S. in one week.
• Verastem will continue with the confirmatory Phase 3 trial, RAMP 301.
• Verastem will continue clinical trials with avutometinib with and without defactinib in RAS/MAPK-driven tumors as part of its Raf And Mek Program or RAMP.

Key Dates

Keywords

AVMAPKI FAKZYNJA CO-PACK, Verastem Oncology, KRAS-mutated LGSOC, FDA approval, Ovarian cancer, RAMP 201, Avutometinib, Defactinib, Oncology, Treatment